FuelCell Energy Inc vs 10X Genomics Inc — how do they compare? FuelCell Energy Inc trades at $17.35 (market cap $1.62B), while 10X Genomics Inc trades at $45.47 (market cap $5.81B). The key difference: 10X Genomics Inc is far larger — about 3.6× FuelCell Energy Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | TXG | |
|---|---|---|
Market Cap | $1.62B | $5.81B |
Sector | Industrials | Health |
52-Week High | $36.01 | $45.80 |
52-Week Low | $3.92 | $11.34 |
Enterprise Value | $1.47B | $5.35B |
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.35, down 18.74% over 24 hours, reflecting recent volatility. The stock shows a bearish technical signal with support at $17 and resistance at $21. Fundamentally, the company reported a net loss of $187.90 million on $158.16 million revenue in 2025, with negative profit margins persisting. Recent news highlights a partnership with Siemens for scalable fuel cell solutions and a $225 million stock offering that caused dilution concerns. Analyst consensus is mixed with a $20.75 price target.
FCEL presents high-risk growth potential driven by AI data center energy demand and strategic partnerships, but faces significant challenges including consistent losses, cash burn, and shareholder dilution. The stock's outlook hinges on execution of commercial projects and path to profitability, with substantial downside risk if growth catalysts fail to materialize.
10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.
While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.
Trailing returns across standard periods
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →